Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042727 · ClinicalTrials.gov registry record · Phase 2
Controlling Rapid Atrial Fibrillation With Dexmedetomidine
A Phase 2 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04042727 is a Phase 2 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 13 participants.
The verdict
NCT04042727, a Phase 2 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.
Interventions
- OTHER Normal Saline
- DRUG Dexmedetomidine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042727
The ClinicalTrials.gov registry entry for NCT04042727 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT04042727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04042727 about?
NCT04042727 is a clinical study titled "Controlling Rapid Atrial Fibrillation With Dexmedetomidine". The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.
What is the current status of trial NCT04042727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-08-21. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04042727?
The interventions under investigation include: Normal Saline (OTHER), Dexmedetomidine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04042727?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.